Teva Closes Emalex Acquisition, Strengthens Neuroscience Pipeline

Teva closed its acquisition of Emalex Biosciences, adding ecopipam, an investigational drug for pediatric Tourette syndrome. Teva paid $700 million at closing with up to $200 million in potential milestone payments. A U.S. NDA submission for ecopipam is expected in the second half of 2026.